{"name":"Gritgen Therapeutics Co., Ltd.","slug":"gritgen-therapeutics-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"GS1191-0445 injection","genericName":"GS1191-0445 injection","slug":"gs1191-0445-injection","indication":"Treatment of a specific type of cancer","status":"phase_3"}]}],"pipeline":[{"name":"GS1191-0445 injection","genericName":"GS1191-0445 injection","slug":"gs1191-0445-injection","phase":"phase_3","mechanism":"GS1191-0445 injection is a therapeutic agent that targets a specific molecular pathway.","indications":["Treatment of a specific type of cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxQck9IdmdhSWsza0ZVT0ZaeDVEWHROX2poanB4UEk0aGpiUDFhSzUwTHhoVm1leHV5SnBXejdsT2JCZ2dQdnpKYnJZXy14cl94ZmR1SDRERURUMHlrbERRdjVNd2t1MWg4QjRpUWV0Y1pVd0poN3hnQzFoM2NFX0tVbGEzSkE3RXdXUUYxck5OTXZFdUZ3UzdEX1hSQkhVMk0xYnhMT2lwenBKT2dtSWpscDIyRjFiek1sbWRVWW1vUGtzS2xreHJtWWlmSUt4ZnAyVG1XWWV3c0xzLUxtVXJ0ZWN1cFdMVWtkZ0xlbWJIR25yYVc0V2NXVmFtR2ROMmRlTVktRUhtcm8xZWM2VHlhMHZzR0VqZmVfNHNxeS1GX2pNaWhXbDh3dEpZNjNVVXVlY21hQzYwdHdTbEdtV3c?oc=5","date":"2025-12-17","type":"pipeline","source":"PR Newswire UK","summary":"Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and Novel Therapy Adoption Landscape | DelveInsight - PR Newswire UK","headline":"Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and Nove","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgNBVV95cUxNTVNxcnB1ZlVyMUZwLWhFYWpQMVgzRmhlOFk0c1VEVHJnWUtiSnRNSnFDbE5USXY1UVpOdzRKWkcxaFR1bElIVmJJZ0Rxd1VBblZYWmgwUHR6bTRId1JiRHZSall3NU1nOGpKUTJyeHpWdVFrYW1QajBLVW9PVjdHc0FuRG5BdEdDZ1FxbzF1dUhURVp3VnRwRjVrRVBXU3JtUXRfZ0hkVXZ2Nk00bm1kUkJCRUE0NU9xTnZuWkRwcEVJNHJLUzlEa2RLX0luS1F3OWp1bTlnWEJBcFZqUllXVkF6cnAwUW5qRWgwYlkzSVl2Zkg0NDgyWm54Zldoczk2bW5PdnRBdWUxQVRaRTZZOGFEa3NkblotQmxOckhYN2Njc3psem9oRDJFNTFrN2d6Q1JqSng4ZDdLWVg3SzNxS1dIbTM1THd3a1phWDJnaFRFU01pa2JoR1hwUU95Z0V3ekhWUTNwYlFpM3hJTEUwXzVFYWY3WjJCei1MYm9wS3BsWmxGZEE?oc=5","date":"2025-12-03","type":"pipeline","source":"PR Newswire","summary":"Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemophilia Prevalence, Strong Uptake of New Drugs, and Emergence of High-cost Gene Th","headline":"Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemop","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQVmFxZEotU1JLdE9xRzlGREtRZzdBWi1Ba2pHMktaNFp5XzJUVi0tLWtTNjZhOHhndmFzRUlELVFYNWJHM1JhTG9EYnFqb2c5Tm5XM21rTFNjRHkycjU3OEdGLVRERG5wcFN2elpfMS1sVmFhZThxY0JIY1E4aTVsLUxHc2hLOG90M1R5V3lGRUx0cUtfdTZoRmw0dmdXVDA?oc=5","date":"2023-11-08","type":"pipeline","source":"Pharmaceutical Technology","summary":"Gritgen Therapeutics’ GMP Gene Therapy Facility, Suzhou, China - Pharmaceutical Technology","headline":"Gritgen Therapeutics’ GMP Gene Therapy Facility, Suzhou, China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQQXZjVEVZMFU2LVpibWF1cVQtVW9kMnlZajM0aUhiLWIwWkZSODBiV2VhUTBuX1Vxa0hjSWl4cDRJTERYVnBFMVRvUW1kNU9CcEM2SEpGdUhyNFpqQURFYmJ5TVo1OUZFN2JpQ0lXN0Q1cUF4Q3BkUnNpcTV1YjNnaHRJT1JUNXg4bDd3VmtqOHB3TTFvcUM5dFlB?oc=5","date":"2023-10-10","type":"pipeline","source":"BioSpace","summary":"Gritgen Therapeutics Launches Commercial GMP Facility in Suzhou, China - BioSpace","headline":"Gritgen Therapeutics Launches Commercial GMP Facility in Suzhou, China","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}